Project Grant R01CA287666
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$700K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Florida, USA
Similar Awards
This $1,220,394 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports a multi-year research study by the Sloan-Kettering Institute for Cancer Research in New York. The project aims to provide a comprehensive molecular and clinical characterization of acute and chronic neurotoxicity following chimeric antigen receptor (CAR) T-cell therapy, an innovative cancer treatment. Key products and services to be delivered under this award include:...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is aimed at pilot testing a metacognitive strategy training (MCST) intervention to address cancer-related cognitive impairment (CRCI) in breast cancer survivors. The $402,401 award, spanning August 2024 to July 2026, will fund a study to examine the feasibility and impact of MCST on cognitive performance, frontoparietal neural circuitry, and task-based brain activity in women treated for...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Dr. Parikh at the Mayo Clinic to conduct clinical trials and develop new protocols for the treatment of chronic lymphocytic leukemia (CLL). Specifically, the $124,230 award will allow Dr. Parikh to: 1) complete two ongoing NCTN-sponsored clinical trials evaluating novel CLL treatments, including analyzing outcomes and biomarkers; and 2) develop the protocol and serve as...
This $691,118 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support a prospective cohort study on survivorship outcomes among real-world patients with relapsed/refractory multiple myeloma (RRMM) treated with chimeric antigen receptor T-cell (CAR T) therapy at the H. Lee Moffitt Cancer Center and Research Institute. The study aims to evaluate the influence of psychosocial and immune-related factors on...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,053,393 to the University of Miami to conduct research aimed at understanding the mechanisms of resistance to non-covalent Bruton's tyrosine kinase (BTK) inhibitors and BTK degraders in patients with chronic lymphocytic leukemia (CLL). The 5-year project, running from July 1, 2024 to June 30, 2029, will elucidate the molecular pathways and signaling mechanisms that lead to...
The National Cancer Institute (NCI) awarded a $638,326 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. The grant supports the adaptation and preliminary evaluation of an intervention called "ENERGIZE-MBC" - a cognitive behavioral therapy for fatigue among women with metastatic breast cancer treated with CDK4/6 inhibitors. The key products and services to be delivered under this grant include: Adapting...
The National Cancer Institute (NCI) awarded a 5-year, $838,395 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Colorado-Denver to investigate how the tumor microenvironment and immune cells impact response to tyrosine kinase inhibitor (TKI) therapy in ALK-positive non-small cell lung cancer. The research aims to determine how neutrophil recruitment by tumor-derived cytokines decreases TKI responsiveness by impairing anti-tumor CD8+ T cell activity. The...
This $1,780,906 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Rutgers, The State University of New Jersey supports research to identify novel biomarkers and therapeutic strategies for chemotherapy-induced cognitive impairment (CICI) in pediatric cancer patients. The key objectives are to: 1) Evaluate if the PARP1 inhibitor veliparib can prevent methotrexate-induced cognitive deficits in mouse models of pediatric T-cell acute lymphoblastic...
This $568,538 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The project aims to understand how the release of the cytokine interleukin-1 alpha alters the immune response during cancer therapy, how this release is controlled by different cell death pathways activated by therapies, and if targeting interleukin-1 alpha can enhance response...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $994,859 to Cytoagents Inc. to support the development and clinical evaluation of CTO1681, a novel compound designed to prevent and mitigate cytokine release syndrome (CRS) in recipients of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. The project aims to determine the preliminary efficacy of CTO1681 in preventing or reducing CRS and immune effector...